Mirati

Alterome Therapeutics Welcomes Andrew S. Chi, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Wednesday, August 23, 2023
General Health, Health, Oncology, Glioma, Molecular biology, BioNTech, KRAS, Huangshan, Translation, Broad Institute, Drug development, Biochemistry, Epigenomics, Cone Health Women's Hospital, CSO, Mirati Therapeutics, Chicago Medical School, Cancer, Drug, Clinical Cancer Research, Lung cancer, Rosalind Franklin University of Medicine and Science, MIT, Boston University, Harvard University, Harvard Medical School, Neuro, Managing editor, Mirati, Neurology, Hospital, Research, FDA, Massachusetts General Hospital, Therapy, Neon, Dana–Farber Cancer Institute, Pharmaceutical industry, Science

Alterome Therapeutics, Inc. , a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.

Key Points: 
  • Alterome Therapeutics, Inc. , a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.
  • “We are excited to welcome Andrew to Alterome during this important phase as we advance our first two programs into the clinic next year,” said Eric Murphy, Ph.D., co-founder, CEO and CSO of Alterome Therapeutics.
  • “Andrew is a talented physician-scientist who brings considerable expertise across all stages of oncology drug development spanning clinical and translational research through global Phase III studies.
  • Before that, he was Senior Director, Clinical Development, at Neon Therapeutics, which was acquired by BioNTech.

Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer

Retrieved on: 
Monday, August 21, 2023
Mirati, KRAS, Lung cancer, Therapy, SGT, Mirati Therapeutics, Patient, NSCLC, Conference, SAN, Pharmaceutical industry, Birth control

SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation of two-year follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

Key Points: 
  • SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation of two-year follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
  • Findings will be presented at the 2023 World Conference on Lung Cancer during the press conference on September 10th10:35 a.m. – 10:40 a.m. SGT / September 9th7:35 p.m. – 7:40 p.m. PT and as a mini-oral presentation in the "Targeted Therapy: KRAS and Beyond" session occurring on September 10th at 4:22 p.m. SGT / 1:22 a.m. PT.

Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Retrieved on: 
Friday, August 11, 2023
Exercise, Attention, SVB Securities, File, Telephone, Mirati Therapeutics, Goldman Sachs, Sale, Prospectus, SAN, Mirati, Security (finance), Therapy

This includes the exercise in full by the underwriters of their option to purchase up to 1,618,705 additional shares of common stock.

Key Points: 
  • This includes the exercise in full by the underwriters of their option to purchase up to 1,618,705 additional shares of common stock.
  • The aggregate gross proceeds to Mirati from this offering were approximately $345.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.
  • Goldman Sachs & Co. LLC acted as the book-running manager for the proposed offering.
  • A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC's website located at http://www.sec.gov .

Mirati Therapeutics Announces Proposed Public Offering

Retrieved on: 
Tuesday, August 8, 2023
Attention, SVB Securities, File, Telephone, Mirati Therapeutics, Goldman Sachs, Sale, Prospectus, SAN, Mirati, Security (finance), Therapy

In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $37.5 million of shares at the public offering price, less the underwriting discounts and commissions.

Key Points: 
  • In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $37.5 million of shares at the public offering price, less the underwriting discounts and commissions.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Goldman Sachs & Co. LLC is acting as the book-running manager for the proposed offering.
  • Leerink Partners LLC is acting as financial advisor for the proposed offering.

Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek

Retrieved on: 
Tuesday, August 8, 2023
Pleasure, Cancer, Mirati Therapeutics, Therapy, Patient, SAN, Pharmaceutical industry, Mirati

SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company today announced that David Meek and the Company mutually agreed for Mr. Meek to step down from his role as CEO and as a member of the Board of Directors. His responsibilities have been assumed by former CEO, president, and founder Charles M. Baum, M.D., Ph.D., acting as interim CEO, while the company conducts a search for a permanent CEO. Mr. Meek will remain as a consultant to the Company through October 15, 2023.

Key Points: 
  • SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company today announced that David Meek and the Company mutually agreed for Mr. Meek to step down from his role as CEO and as a member of the Board of Directors.
  • His responsibilities have been assumed by former CEO, president, and founder Charles M. Baum, M.D., Ph.D., acting as interim CEO, while the company conducts a search for a permanent CEO.
  • Mr. Meek will remain as a consultant to the Company through October 15, 2023.
  • "I am proud of the accomplishments Mirati has achieved with the successful launch of KRAZATI and advancing an innovative pipeline," said David Meek.

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, August 3, 2023
Employment, Therapy, RSU, Mirati Therapeutics, SAN, Pharmaceutical industry, Life insurance, Mirati

SAN DIEGO, Aug. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to a new employee with a grant date of August 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company.

Key Points: 
  • SAN DIEGO, Aug. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to a new employee with a grant date of August 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employee received options to purchase 5,189 shares of Mirati's common stock and 3,067 restricted stock units ("RSUs").
  • The options have an exercise price of $30.02 per share, which is equal to the closing price of Mirati's common stock on August 1, 2023, (the "Grant Date").

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mirati Therapeutics, Inc. – MRTX

Retrieved on: 
Wednesday, August 2, 2023
LLP, European Directive on Traditional Herbal Medicinal Products, Mirati Therapeutics, NSCLC, Lung cancer, Committee, EMA, Conditional, Patient, Committee for Medicinal Products for Human Use, Mirati, MAA, Indoor Living, Pomerantz, News, CHMP, Private investigator

NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. (“Mirati” or the “Company”) (NASDAQ: MRTX).

Key Points: 
  • NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. (“Mirati” or the “Company”) (NASDAQ: MRTX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Mirati and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX

Retrieved on: 
Thursday, July 27, 2023
LLP, European Directive on Traditional Herbal Medicinal Products, Mirati Therapeutics, NSCLC, Lung cancer, Committee, EMA, Conditional, Patient, Committee for Medicinal Products for Human Use, Mirati, MAA, Indoor Living, Pomerantz, News, CHMP, Private investigator

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. (“Mirati” or the “Company”) (NASDAQ: MRTX).

Key Points: 
  • NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. (“Mirati” or the “Company”) (NASDAQ: MRTX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Mirati and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023

Retrieved on: 
Tuesday, July 25, 2023
Mirati, Therapy, Mirati Therapeutics, SAN, Communications satellite, Broadcasting, Cryptocurrency

SAN DIEGO, July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023.

Key Points: 
  • SAN DIEGO, July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023.
  • During a conference call at 4:30 p.m.
  • ET / 1:30 p.m. PT on August 8, company executives will provide company updates and review financial results.
  • A replay of the call will be available approximately 2 hours after the event has ended at the same website.

Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director

Retrieved on: 
Friday, June 23, 2023
Amgen, Gilead Sciences, Bachelor of Science, Drug development, University, Mirati Therapeutics, CancerVax, Cancer, Frazier Healthcare Partners, Bristol Myers Squibb, Vanderbilt University, Eli Lilly, Salk Institute for Biological Studies, NEA, Acquisition, Trustee, SAN, Therapy, New Enterprise Associates, Pharmaceutical industry, Management, Science, Pharmacy, Mirati, Pfizer

SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.

Key Points: 
  • SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.
  • Dr. Gallagher has over 30 years of strategic, commercial, business development and drug development leadership experience in the life sciences industry.
  • A veteran board director, Dr. Gallagher currently serves as a board member of PMV Pharma, Atara Biotherapeutics and, until its recent acquisition by Bristol Myers Squibb in August 2022, Turning Point Therapeutics.
  • Dr. Gallagher commented, "I am thrilled to join the Mirati Therapeutics board of directors during this transformational time for the company.